Patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test that is performed after treatment, according to

Patients who are at a higher risk of their lung cancer returning can be identified by a personalised blood test that is performed after treatment, according to

Markers in our blood – ‘fingerprints’ of infection – could help identify individuals who have been infected by SARS-CoV-2, the coronavirus that causes

Researchers have developed a free, open-source toolkit that allows laboratories in developing countries to produce their own tools for COVID-19 research and

First study of SAMBA II devices on hospital wards finds patient time on COVID ‘holding wards’ was almost halved. Researchers say faster tests helped expedite access to life-saving treatments such as organ transplants – and might make all the difference later this year.

The diagnostic industry in countries such as Germany, South Korea and China lead the pack on getting coronavirus tests ready for market. Researchers warn that lax EU regulations could see it become a “dumping ground” for bad tests.

A new test for infection with SARS-CoV2 that which inactivates the virus at the point of sampling, has been developed by a team of researchers at the Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID). It is now being used to test and screen frontline NHS staff at a Cambridge hospital.

A new rapid diagnostic test for COVID-19, developed by a University of Cambridge spinout company and capable of diagnosing the infection in under 90 minutes, is being deployed at Cambridge hospitals, ahead of being launched in hospitals nationwide.

Proteins in our blood could in future help provide a comprehensive ‘liquid health check’, assessing our health and predicting the likelihood that we will we will develop a range of diseases, according to research published today in Nature Medicine.